OSI Pharmaceuticals, Inc. Announces the Results of its Offer to Purchase its 2% Convertible Notes and a Change in the Expiration Time of its Offer to Purchase its 3% Convertible Notes

MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (the “Company”) announced today that all of its 2% Convertible Senior Subordinated Notes due 2025 (the “2% Notes”) have been surrendered for conversion, as provided for in the Indenture governing the notes. As a result, no 2% Notes remain outstanding and the Company has terminated the Offer to Purchase the 2% Notes that the Company was required to make pursuant to Section 3.9 of the Indenture.